{
  "abstract": "Background and Importance Complementary therapies, particularly herbal products (HP), are frequently used by oncology patients. However, unsupervised consumption may result in interactions that compromise the efficacy and safety of anticancer treatments (AT).Aim and Objectives The primary objective was to identify HP with the highest potential for interaction with oncological treatment. Secondary objectives: to detect AT most frequently involved, to describe the most common AT–HP associations, and to assess their potential clinical consequences.Material and Methods We conducted a prospective longitudinal study in a tertiary hospital. Adult patients receiving oncological treatment at the Hospital Outpatient Clinic (HOC) (April–June 2025) were included. Patients enrolled in clinical trials or with haematological malignancies were excluded. Socio-demographic data were collected from the electronic health record (HCIS ), and treatment-related data from the hospital prescribing system (FarmaTools ).HP consumption was assessed through a 7-item questionnaire designed by the research team based on validated surveys and completed during treatment. Potential interactions were analysed using recognised bibliographic sources.1-4 Results A total of 112 patients were included: 62 (55%) women, median age 64 (IQR 57–72) years. A total of 104 patients (92.9%) reported HP consumption, leading to 443 potential interactions identified in 95 (91.3%) patients. These interactions involved 29 (64.4%) AT and 25 (55.6%) HP.The AT most frequently involved was paclitaxel (50; 11.3%), followed by cyclophosphamide (37; 8.4%), doxorubicin (35; 7.9%), and docetaxel (34; 7.7%). The HP with the highest number of potential interactions were garlic (11.5%), turmeric (10.2%), rosemary (7.7%), pepper (7.2%), chamomile (6.5%) and cayenne (5.9%). The most frequent associations were pepper–carboplatin (16; 15.4%), garlic–carboplatin (15; 14.4%), chamomile–carboplatin (13; 12.5%), thyme–carboplatin (13; 12.5%), oregano–carboplatin (12; 11.5%) and pepper–bevacizumab (12; 11.5%), mainly increasing bleeding risk.Conclusion and Relevance Drug–herb interactions are frequent among oncology patients. Paclitaxel was the AT with the highest number of potential interactions, whereas carboplatin-related associations affected the largest number of patients. Systematic identification of HP consumption and patient education are essential to ensure treatment safety.References and/or Acknowledgements 1. https://gruposdetrabajo.sefh.es/gedefo/muro-solidario2. 2017;56(4):317–337. doi:10.1007/s40262-016-0450-z3. 2023;149:2855–2882. doi:10.1007/s00432-022-04172-14. https://www.sefh.es/bibliotecavirtual/interacc2014/InteraccionesFarmacoloigicas_pr.pdfConflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Hospital Universitario Ramón Y Cajal- Irycis, Pharmacy Department, Madrid, Spain"
      ],
      "name": "C Calleja-Fernández"
    },
    {
      "affiliations": [
        "Hospital Universitario Ramón Y Cajal- Irycis, Pharmacy Department, Madrid, Spain"
      ],
      "name": "N Espadas-Hervas"
    },
    {
      "affiliations": [
        "Hospital Universitario Ramón Y Cajal- Irycis, Pharmacy Department, Madrid, Spain"
      ],
      "name": "MA Parro Martin"
    },
    {
      "affiliations": [
        "Hospital Universitario Ramón Y Cajal- Irycis, Pharmacy Department, Madrid, Spain"
      ],
      "name": "J Saez-De La Fuente"
    },
    {
      "affiliations": [
        "Hospital Universitario Ramón Y Cajal- Irycis, Pharmacy Department, Madrid, Spain"
      ],
      "name": "M Sánchez-Cuervo"
    },
    {
      "affiliations": [
        "Hospital Universitario Ramón Y Cajal- Irycis, Pharmacy Department, Madrid, Spain"
      ],
      "name": "M Martin Rufo"
    },
    {
      "affiliations": [
        "Universidad De Alcalá De Henares, Pharmacy Faculty, Madrid, Spain"
      ],
      "name": "I Santamaria-Rodriguez"
    },
    {
      "affiliations": [
        "Universidad De Alcalá De Henares, Pharmacy Faculty, Madrid, Spain"
      ],
      "name": "M Sanchez-Heras"
    },
    {
      "affiliations": [
        "Hospital Universitario Ramón Y Cajal- Irycis, Pharmacy Department, Madrid, Spain"
      ],
      "name": "A Álvarez-Diaz"
    },
    {
      "affiliations": [
        "Universidad Francisco De Vitoria, Pharmacy Faculty, Madrid, Spain"
      ],
      "name": "A Palacios-Morales"
    }
  ],
  "title": "4CPS-236 Potential interactions between herbal products and oncological treatment in a hospital outpatient clinic",
  "uid": "73e56e59-a685-5580-bc81-e5d2722ef4cd"
}